- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07087535
- Original Trial
Midterm Follow up Outcomes of (SASJ) in Management of Morbid Obesity
Midterm Follow up Outcomes of Single Anastomosis Sleeve Jejunal Bypass (SASJ) in Management of Morbid Obesity
Obesity is a critical health problem associated with an increased risk of cardiovascular disease, diabetes, and cancers, affecting both the quality of life and life expectancy . The increasing prevalence of obesity and comorbid conditions requires effective treatment and prevention . Previous evidence has demonstrated that bariatric surgery is associated with greater and longer-term weight loss than non-surgical management Thus, in patients with a body mass index of ≥ 40 or ≥ 35 kg/m2 with co-morbidities, bariatric surgery is the most effective treatment option that not only promotes weight loss but also improves comorbid conditions . However, like any surgical procedure, several complications can occur . The development of nutritional deficiencies is a complication which may be life-threatening; therefore, bariatric surgery requires careful consideration .
The most frequently performed surgery for obesity worldwide is the laparoscopic sleeve gastrectomy (LSG), the Roux-en-Y gastric bypass (RYGB), and more recently, the one anastomosis gastric bypass (OAGB) .
One newly developed weight loss procedure, the single sleeve ileal anastomosis bypass (SASI), has been developed as a modification to Santoro's operation (sleeve gastrectomy with transit bipartition SG + TB) . Since no duodenal division or manual anastomosis is required, the procedure allows easy endoscopic access to the duodenum . noted that SASI has the following advantages over other bariatric procedures: SASI has a shorter operative time compared to other procedures; 2) easy access to the duodenum and biliary tree endoscopically; 3) SASI does not divide the duodenum, thus eliminating the possibility of duodenal stump leakage, a serious complication with an incidence range between; 4) the tension on the anastomosis lower than other techniques; 5) there are no blind loops, excluded segments, or foreign bodies; 6) SASI is completely reversible .
Single anastomosis sleeve jejunal (SASJ) bypass, which is the focus of this study, is a modification of SASI using a shorter biliopancreatic limb length compared to SASI to prevent long-term nutritional complications . The SASJ bypass appears to be safer than the SASI procedure in patients with excessive weight loss and nutritional deficiencies and is simpler due to its improved surgical ergonomics .
Aim of the Work This study aims to evaluate the three-year outcomes of SASJ bypass as a primary bariatric procedure in a tertiary bariatric center for weight loss, comorbidity resolution, and both early and late complications.
Study Overview
Status
Conditions
Detailed Description
A retrospective study with prospective collected data included a case series of consecutive bariatric patients who underwent SASJ bypass in Sohag university hospitals between the 1st of January 2019 and the 31st of june 2023. The analysis in the present study included data of all the patients who underwent SASJ as bariatric procedure. All patients were approved as candidates for bariatric surgery by a multidisciplinary screening team, between 18 and 65 years of age and a BMI more than 40 kg/m2 or BMI of more than 35 kg/m2 combined with comorbidities.
All the required data have been collected from the patients' files at Sohag university hospitals out-patient clinic. To update follow up data for missing patients, a postal questionnaire will be sent to all patients to retrieve the latest outcome. Patients who will not respond will receive a phone call and email if applicable. The postal questionnaire contained questions about:
- Current and lowest weight after surgery.
- Current comorbidities and medication.
- Possible complaints / complications.
- Any surgical intervention related to the SASJ bypass. In case of non-response, the data of the last visit either in hospital or out-patient clinic were used as a final outcome.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Sohag, Egypt, 82515
- Sohag Hospital University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age from 18 to 65 years old.
- Both sexes.
- Body mass index (BMI) > 35 with comorbidities or BMI > 40 with or without comorbidities.
- Primary bariatric procedure.
- Follow up period 2 years or more after SASJ.
Exclusion Criteria:
- Follow up period less than 2 years.
- Previous laparoscopic metabolic surgery
- Patients with huge anterior abdominal wall hernias.
- Cirrhotic patients.
- Pregnant or lactating females.
- Unfit patients for anesthesia.
- patients requiring revisional bariatric surgery.
- Patients with any contraindications to laparoscopic surgery.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
weight loss outcomes
Time Frame: 2 years
|
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
comorbidities readmission reoperation
Time Frame: 2 years
|
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Soh-Med--25-6-9MS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Morbid Obesity Requiring Bariatric Surgery
-
ClinTrio Ltd.UnknownMorbid Obesity Requiring Bariatric SurgeryBelgium, Germany, Portugal, Austria, Netherlands, Poland, Saudi Arabia
-
General Committee of Teaching Hospitals and Institutes...CompletedMorbid Obesity Requiring Bariatric SurgeryEgypt
-
Mansoura UniversityCompleted
-
Sercan YUKSEL, MDCompletedMorbid Obesity Requiring Bariatric SurgeryTurkey (Türkiye)
-
Sercan YUKSEL, MDCompletedMorbid Obesity Requiring Bariatric SurgeryTurkey (Türkiye)
-
Yigit DUZKOYLUActive, not recruitingMorbid Obesity Requiring Bariatric SurgeryTurkey (Türkiye)
-
University Hospital, GenevaRecruitingMorbid Obesity Requiring Bariatric SurgerySwitzerland
-
Kirsehir Ahi Evran UniversitesiIstinye UniversityNot yet recruitingMorbid Obesity | Obesity & Overweight | Morbid Obesity Requiring Bariatric Surgery
-
Central Hospital, Nancy, FranceUnknownMorbid Obesity | Gastric Bypass | Bariatric Surgery | Laparoscopic Bariatric Surgery | Robotic Bariatric SurgeryFrance
-
The Third Xiangya Hospital of Central South UniversityRecruitingObesity | Bariatric Surgery | Bariatric Surgery (Sleeve Gastrectomy )China